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Abstract
Background: The protein tyrosine phosphatase, receptor type, N
polypeptide 2 (PTPRN2) gene may play a role in cancer; however,
no study has focused on the associations of genetic variants within
the PTPRN2 gene with age at onset (AAO) of cancer.
Methods: This study examined 220 single nucleotide
polymorphisms (SNPs) within the PTPRN2 gene in the Marshfield
sample with 716 cancer cases (any diagnosed cancer, excluding
minor skin cancer) and 2,848 non-cancer controls. Multiple logistic
regression model and linear regression model in PLINK software
were used to examine the association of each SNP with the risk
of cancer and AAO, respectively. For survival analysis of AAO,
both classic Cox regression and Bayesian survival analysis using
the Cox proportional hazards model in SAS v. 9.4 were applied to
detect the association of each SNP with AAO. The hazards ratios
(HRs) with 95% confidence intervals (CIs) were estimated.
Results: Single marker analysis identified 10 SNPs associated
with the risk of cancer and 9 SNPs associated with AAO (p < 0.05).
SNP rs7783909 revealed the strongest association with cancer
(p = 6.52x10-3); while the best signal for AAO was rs4909140 (p
= 6.18x10-4), which was also associated with risk of cancer (p =
0.0157). Classic Cox regression model showed that 11 SNPs were
associated with AAO (top SNP rs4909140 with HR = 1.38, 95%CI
= 1.11-1.71, p = 3.3x10-3). Bayesian Cox regression model showed
similar results to those using the classic Cox regression (top SNP
rs4909140 with HR = 1.39, 95%CI = 1.1-1.69).
Conclusions: This study provides evidence of several genetic
variants within the PTPRN2 gene influencing the risk of cancer
and AAO, and will serve as a resource for replication in other
populations.
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Cancer continues to remain a significant public health issue

International Library

The protein tyrosine phosphatase, receptor type, N polypeptide
2 (PTPRN2) gene (also known as IAR, ICAAR, PTPRP, IA-2beta,
R-PTP-N2) is located at 7q36 [8,9]. The PTPRN2 is expressed
primarily in human brain and pancreas and in mouse brain, pancreas,
and insulinoma cell lines [10,11]. One methylation study found that
PTPRN2 showed highly significant hypermethylation in squamous
cell lung cancer tissue [12]. Another gene expression profile study
suggested that PTPRN2 was associated with metastatic prostate
cancer [13]. A recent study reported that PTPRN2 was expressed
predominantly in endocrine and neuronal cells, where it might
function in exocytosis and suggested as a novel candidate biomarker
and therapeutic target in breast cancer [14].
However, no study has focused on the associations of genetic
variants of PTPRN2 gene with age at onset (AAO) of cancer.
Furthermore, Bayesian methods have become increasingly popular
in many areas of scientific research including genetic association
studies, which may have some advantages in flexibility, and
incorporating information from previous studies and dealing with
sparse-data [15-17]. In this study, we explored the associations of
220 SNPs in the PTPRN2 gene with AAO of cancer using a Bayesian
survival analysis in a Caucasian sample.

Subjects and Methods
The Marshfield sample

Introduction

ClinMed

globally. It is the leading cause of death in both developed and
emerging economies [1]. In 2012, there were 14.1 million new cancer
cases, 8.2 million cancer mortalities, and 32.6 million people living
with cancer globally [2]. Cancers are caused by a complex interplay
between genetic predisposition and environment. Family and
twin studies have shown the estimated effects of heritability of the
colorectal cancer (35%) [3], breast cancer (25-30%) [3-5], prostate
cancer (42-58%) [3,6], and lung cancer (25-26%) [3,7].

The Marshfield sample is from the publicly available data in
A Genome-Wide Association Study on Cataract and HDL in the
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Personalized Medicine Research Project Cohort - Study Accession:
phs000170.v1.p1 (dbGaP). The details about these subjects were
described elsewhere [18,19]. Cancer cases were defined as any
diagnosed cancer excluding minor skin cancer; while AAO cancer
was defined by date of the earliest cancer diagnosis in the registry.
Social factors used in this study were age, gender, alcohol use in
the past month (yes or no), and smoking status (never smoking,
current smoking and past smoking). Obesity was determined as a
body mass index (BMI) ≥ 30. Genotyping data using the ILLUMINA
Human660W-Quad_v1_A are available for 3564 Caucasian
individuals (716 cancer cases and 2848 controls). Within the PTPRN2
gene, 220 SNPs were available and therefore included in the analysis.

Statistical methods
Linear and logistic regression models in PLINK software:
The categorical variables were presented as frequencies and
percentages. The continuous variables were reported as the means
± standard deviation. Quality-control and association analyses
were implemented using PLINK V1.07 [20]. First, Hardy-Weinberg
equilibrium (HWE) was tested for all the SNPs using the controls;
then, minor allele frequency (MAF) was determined for each
SNP. Multiple logistic regression analysis of each SNP with risk
of cancer as a binary trait, adjusted for sex, age*age, alcohol use,
smoking status, and obesity, was performed using PLINK; while
the asymptotic p-values were observed and the odds ratio (OR) and
95% confident interval (CI) were estimated. Furthermore, AAO
values were firstly log transformed, then multiple linear regression
analysis of each SNP with log transformed AAO of cancer, adjust for
sex, alcohol use, smoking status, and obesity was performed; while
the asymptotic p-values were observed and the regression coefficient
(β) and 95% CI were estimated. To control for type I errors arising
from multiple hypothesis testing, a false discovery rate (FDR) was
defined in Benjamini and Hochberg [21] as the expected proportion
of false discoveries. In addition, empirical p-values were generated by
100,000 permutation tests using Max (T) permutation procedure. In
this procedure, pointwise estimate of an individual SNP’s significance
(empirical pointwise p-values) was calculated.
Cox proportional hazards models in PROC PHREG: The
proportional hazards model or Cox regression model, is widely used
in the analysis of time-to-event data to explain the effect of explanatory
variables on hazard rates. The PHREG procedure fits the Cox model
by maximizing the partial likelihood function; this eliminates the
unknown baseline hazard and accounts for censored survival times.
In the Bayesian approach, the partial likelihood function is used as
the likelihood function in the posterior distribution [22]. In the nonBayesian analysis, the Akaike information criterion (AIC) was used
as a measure of goodness of model fit that balances model fit against
model simplicity [23,24]. Bayesian Cox regression can be requested
by using the BAYES statement in the PHREG procedure. A Markov
chain Monte Carlo (MCMC) method by Gibbs sampling was used
to simulate samples from the posterior distribution. In a Bayesian
analysis, a Gibbs chain of samples from the posterior distribution
was generated for the model parameters. Summary statistics (mean,
standard deviation, quartiles, the highest posterior density (HPD) and
credible intervals, correlation matrix) and convergence diagnostics
(Geweke; the effective sample size; and Monte Carlo standard errors)
were computed for each parameter, as well as the correlation matrix
and the covariance matrix of the posterior sample. Trace plots,
posterior density plots, and autocorrelation function plots were
created for each parameter [17]. The hazards ratios (HRs) with 95%
CIs were estimated.
For the present study of the AAO, the normal prior was chosen
for the coefficients. In Bayesian analysis, a deviance information
criterion (DIC) is available for model comparison instead of AIC.
DIC is a hierarchical modeling generalization of the AIC; while DIC
is intended as a generalization of AIC [25]. The following program
showed one SNP rs4909140, sex, alcohol use, smoking status, and
obesity with the AAO of cancer. The rs4909140 has 3 genotypes
- G_G, G_T and T_T, respectively; while the T_T genotype was
considered as the reference.
Wang et al. Int J Clin Biostat Biom 2015, 1:1

Table 1: Descriptive characteristics of cases and controls
Non-Cancer

Cancer

2848

716

Males

1135(40%)

340(47%)

Females

1713(60%)

376(53%)

No

1700(60%)

422(59%)

Yes

1148(40%)

294(41%)

No

1060(37%)

288(40%)

Yes

1783(63%)

425(60%)

1487(52%)

327(46%)

Number
Sex, N (%)

Obesity, N (%)

Alcohol, N (%)

Smoking, N (%)
Never
Current

254(9%)

54(7%)

1104(39%)

331(47%)

65.1 ± 11.3

71.1 ± 10.3

46-90

46-90

Mean ± SD

-

64.2 ± 12.8

Range

-

23-90

Past
Age, years
Mean ± SD
Range
Age at onset, years

proc phreg data= aao;
class sex(ref ="1") obesity (ref ="1") alcohol(ref ="1") smoking(ref
="1") rs4909140 (ref = "T_T") ;
model canceraao*statuscan(0) = sex obesity alcohol smoking
rs4909140/risklimits;
bayes seed =1000 nbi =10000 nmc =100000 thin =10 seed =1000
cprior=normal(var =1e6) outpost = out plots = density;
hazardratio rs4909140;
run;
Descriptive statistics and Cox regression analyses were conducted
with SAS v.9.4 (SAS Institute, Cary, NC, USA).

Results
Genotype quality control and descriptive statistics
We removed 1 SNP with HWE p < 10-4. All other 219 SNPs
were in HWE with MAF > 1% in the controls. The demographic
characteristics of the subjects in the study are presented in Table
1. There were slightly more females than males in both cases and
controls. The age ranged from 46 to 90 years and AAO of cancer
ranged from 23 to 90 years.

Multiple linear and logistic regression analyses using PLINK
Using a single marker analysis, we identified 10 SNPs associated
with the risk of cancer and 9 SNPs associated with AAO (p < 0.05) in
the Marshfield sample (Table 2). SNP rs7783909 revealed the strongest
association with cancer (p = 6.52x10-3); while the best signal for AAO
was rs4909140 (p = 6.18x10-4), which was also associated with risk of
cancer (p = 0.0157). For the 10 SNPs associated with risk of cancer,
the FDR was 90%; while the FDR for the two AAO mostly associated
SNPs (rs4409140 and rs1670340) were 21% and 39%, respectively.
Furthermore, we conducted a permutation test in PLINK and found
that all the cancer and or AAO associated SNPs had empirical point
wise p-values p < 0.05 using a permutation test (Table 2).

Classic and Bayesian Cox regression analyses using PROC
PHREG
Classic Cox regression model showed that 11 SNPs were associated
with AAO (top SNP rs4909140 with HR=1.38, 95%CI = 1.11-1.71, p
= 3.3x10-3). The HRs based on the Bayesian survival analyses revealed
similar results to those using the non-Bayesian analyses results (Table
3). The DIC for the 11 SNPs in the Bayesian analyses were similar to
ISSN: 2469-5831
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Table 2: SNPs within the PTPRN2 gene associated with risk and age at onset of cancer using PLINK (p < 0.05)
SNP

Positiona

Alleleb

MAFc

HWEd

OR-Cancere

p-Cancerf

EMPg

β-AAOh

p-AAOi

EMPj

rs7783909

157287177

A

0.15

0.413

1.42(1.1-1.83)

6.52E-03

4.0E-03

-0.017

0.0713

0.0739

rs4909140

157721662

G

0.46

0.727

1.16(1.03-1.31)

1.57E-02

1.1E-02

-0.017

6.18E-04

4.0E-03

rs10244830

157674626

T

0.35

0.318

0.84(0.73-0.97)

1.81E-02

1.4E-02

0.002

0.7115

0.699

rs7795387

157764272

G

0.22

0.409

0.74(0.57-0.96)

2.23E-02

2.2E-02

0.002

0.844

0.856

rs6970487

157712908

G

0.42

0.561

0.86(0.76-0.98)

2.55E-02

2.8E-02

0.01

0.0653

0.0579

rs4595081

157700684

T

0.42

0.475

0.86(0.76-0.98)

2.69E-02

2.9E-02

0.01

0.065

0.058

rs6944416

157708321

G

0.42

0.623

0.86(0.76-0.98)

2.78E-02

3.0E-02

0.01

0.064

0.06

rs17837789

157128182

G

0.15

0.186

0.63(0.41-0.96)

3.29E-02

2.8E-02

-0.027

0.159

0.155

rs920023

157427075

G

0.24

0.768

0.8(0.65-0.99)

4.03E-02

3.9E-02

0.016

0.0751

0.0739

rs4909289

157647665

A

0.26

0.82

0.82(0.68-0.99)

4.85E-02

4.3E-02

0.003

0.699

0.687

rs1670340

157963783

C

0.49

0.385

0.97(0.86-1.1)

0.654

0.687

-0.016

1.69E-03

2.0E-03

rs1630862

157961357

G

0.45

0.965

0.97(0.86-1.09)

0.588

0.598

-0.013

1.17E-02

0.012

rs11760246

157523437

T

0.37

0.016

1.04(0.91-1.19)

0.529

0.54

0.013

1.81E-02

0.025

rs1268391

157111665

C

0.32

0.841

0.96(0.83-1.12)

0.606

0.62

-0.015

2.16E-02

0.023

rs7777448

157724510

A

0.39

0.99

0.98(0.86-1.12)

0.736

0.712

-0.013

2.38E-02

0.034

rs3752374

157581981

G

0.05

0.662

1.73(0.73-4.11)

0.239

0.155

-0.07

3.29E-02

0.04

rs10949670

157388704

T

0.39

0.142

1.0(0.88-1.14)

0.956

0.95

0.011

3.95E-02

0.043

rs12698149

rs12698149

T

0.39

0.238

1.05(0.92-1.19)

0.494

0.504

0.011

3.95E-02

0.045

a
Physical position(bp); b Minor allele; c Minor allele frequency; d Hardy-Weinberg equilibrium test p-value; e Odds ratio for the risk of cancer based on logistic regression
using PLINK; f p-value for the risk of cancer based on logistic regression; g empirical p-value for the risk of cancer generated by 100,000 permutation tests using Max
(T) permutation procedure implemented in PLINK; h Regression coefficient for AAO of cancer based on linear regression using PLINK; i p-value for AAO of cancer
based on linear regression ; j empirical p-value for AAO of cancer generated by 100,000 permutation tests using Max (T) permutation procedure implemented in PLINK.
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Figure 1: Trace plot, autocorrelation function plot, and posterior density plot for rs4909140.

those of AIC using classic Cox model.
The trace plot, posterior density plot, and autocorrelation function
plot based on Bayesian analysis (Figure 1) indicated that the Markov
chain had stabilized with good mixing for rs4909140. The posterior
density plot, which estimates the posterior marginal distributions
for the 7 regression coefficients showed a smooth, unimodal shape
Wang et al. Int J Clin Biostat Biom 2015, 1:1

for the posterior marginal distribution (Figure 2). Table 4 shows the
posterior summary of rs4909140 with HR = 1.39, 95% CI = 1.1-1.69.

Discussion
In this study, we identified 10 SNPs associated with the risk of
cancer and 9 SNPs with AAO using the PLINK software and 11 SNPs
ISSN: 2469-5831
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Figure 1: Trace plot, autocorrelation function plot, and posterior density plot for rs4909140.
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Figure 2: The posterior density plots for the 7 regression coefficients.

revealed associations with AAO using Cox survival model in SAS.
Bayesian Cox regression model revealed similar findings to those
using the classic Cox regression. To our knowledge, this is the first
candidate gene study to provide evidence of several genetic variants
within the PTPRN2 gene associated with the risk of cancer and AAO.
Wang et al. Int J Clin Biostat Biom 2015, 1:1

Previous studies have showed that PTPRN2 is an autoantigen
for type 1 diabetes which is an insulin-dependent diabetes mellitus
and autoimmune disease; while PTPRN2 is reactive with type 1
diabetes patient sera and is likely to be an islet cell antigen useful in
the preclinical screening of individuals for the risk of type 1 diabetes
ISSN: 2469-5831
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Table 3: SNPs within the PTPRN2 gene associated with AAO of cancer using PROC PHREG (p<0.05)
SNP

Positiona

Alleleb

GTc

HRd

pe

AICf

HRg

DICh

rs13239831

157124954

T

C-C

0.66(0.48-0.91)

1.16E-02

7914.6

0.68(0.48-0.9)

7914.5

rs7783909

157287177

A

A-A

1.67(1.11-2.5)

1.36E-02

7954.4

1.67(1.03-2.36)

7954.3

rs6942917

157385952

A

A-G

1.27(1.07-1.51)

6.4E-03

7952.6

1.27(1.06-1.49)

7952.6

rs4716881

157509808

A

A-A

1.32(1.03-1.71)

3.03E-02

7954.0

1.33(1.0-1.66)

7953.9

rs4716535

157516571

T

C_T

1.23(1.05-1.44)

1.08E-02

7952.8

1.0(0.7-1.3)

7952.8

rs9654713

157607912

A

A_G

1.23(1.06-1.44)

8.4E-03

7953.1

1.24(1.06-1.44)

7953.1

rs4909140

157721662

G

G_G

1.38(1.11-1.71)

3.3E-03

7951.4

1.39(1.1-1.69)

7951.4

rs7777448

157724510

A

A_A

1.36(1.04-1.63)

2.35E-02

7902.7

1.3(1.01-1.6)

7902.7

rs7777968

157773101

G

A_G

1.55(1.08-2.24)

1.88E-02

7953.8

1.6(1.04-2.22)

7953.8

rs1670356

157953979

A

A‑C

0.83(0.71-0.97)

1.75E-02

7940.7

0.83(0.7-0.96)

7940.7

rs1670340

157963783

C

C_C

1.28(1.04-1.58)

2.19E-02

7954.8

1.29(1.03-1.56)

7954.7

Physical position(bp); Minor allele; Tested Genotype comparing with the reference; Hazards ratio for the tested genotype based on classic Cox regression analysis
using PROC PHREG; e p-value for the tested genotype based on classic Cox regression analysis; f Akaike information criterion (AIC) value based on classic Cox
regression analysis; g Hazards ratio for the tested genotype based on Bayesian Cox regression analysis; h Deviance information criteria (DIC) value based on Bayesian
Cox regression analysis.
a

b

c

d

Table 4: Posterior summary and hazard ratio for rs4909140
SNP

GTa

rs4909140

T_T
G_G

βb
0.32

SEc

β-Lower HPDd

β-Upper HPDe

HRf

0.11

0.1

0.52

1.39

HR-Lower HPDg

HR-Upper HPDh

1.11

1.69

Genotype comparing with the reference; Regression coefficient for G_G genotype comparing with T_T; Standard error for the regression coefficient; d Lower 95%
HPD for the regression coefficient; e Upper 95% HPD for the regression coefficient; f Hazards ratio for G_G genotype comparing with T_T; g Lower 95% HPD of hazards
ratio; h Upper 95% HPD of hazards ratio.
a

b

[10,26-28]. Animal model studies revealed that this gene may be
functioned in the regulation of insulin secretion [11,29-32]. Recently,
another study suggested that PTPRN2 (IA-2beta) is one of the genes
potentially relevant to insulin and neurotransmitter release [33].
Furthermore, several studies have reported that the PTPRN2 gene
may be involved in squamous cell lung cancer tissue [12], metastatic
prostate cancer [13] and breast cancer [14]. However, the mechanism
is not clear. It has been hypothesized that recurrent or clonal somatic
mutation underlies the initiation of autoimmune disease such as
type 1 diabetes [34]; while many cancers elicit antibodies that are
also found in autoimmune diseases [35]. Therefore, PTPRN2 may be
one of the mechanisms linking autoimmune diseases to cancers. In
addition, insulin, insulinlike growth factor 1, and insulinlike growth
factor 2 signaling through the insulin receptor and the insulinlike
growth factor 1 receptor could induce tumorigenesis, accounting to
some extent for the link between diabetes, metabolic syndrome and
cancers [36,37].
However, no association study of genetic polymorphisms
within the PTPRN2 gene with the risk of cancer and AAO has been
conducted. The present study provides the first evidence of several
genetic variants within the PTPRN2 gene is associated with the risk
and AAO of cancer using multiple logistic and linear regression
models. We identified the main effects and permutation p-values
for single SNPs. Furthermore, we conducted Bayesian survival
analysis of genetic variants with AAO. Bayesian methods may have
some advantages in flexibility and incorporating information from
previous studies. For example, Bayesian method may provide an
alternative approach to assessing associations that alleviates the
limitations of p-values at the cost of some additional modelling. It
has recently made great inroads into many areas of science, including
the assessment of associations between genetic variants and disease
or related phenotypes [15]. We also realized some limitations in this
study. First, the definition of cancer status in the Marshfield sample
was broad (including any diagnosed cancer omitting minor skin
cancer). It would be more informative to investigate the association
of PTPRN2 gene with particular types of cancer. Furthermore, our
current findings might be subject to type I error and findings need to
be replicated in additional samples.

Conclusion
This study provides evidence of several genetic variants within
the PTPRN2 gene influencing the risk and AAO of cancer. Future
functional study of this gene may help to better characterize the
Wang et al. Int J Clin Biostat Biom 2015, 1:1

c

genetic architecture of cancers.
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